Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 11/20 | 0.45 |
| ▸ | MAPK8 | P45983 | 7/20 | 0.44 |
| ▸ | MAPK9 | P45984 | 7/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 7/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3637143 | 0.82 | PIK3CA (0.55) | RAB9ANPC1PDGFRBPDGFRAPIK3CA | |
| SCHEMBL20306100 | 0.78 | PDGFRB (0.50) | HCAR3RAB9ANPC1PDGFRBPDGFRA | |
| SCHEMBL5759397 | 0.77 | NPC1 (0.57) | HCAR3RAB9ANPC1PIK3CAMAPK8 | |
| SCHEMBL3638703 | 0.77 | PIK3CA (0.75) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL5759348 | 0.77 | MAPK1 (0.53) | RAB9APDGFRBPDGFRAPIK3CAMAPK8 | |
| SCHEMBL4340922 | 0.75 | MAPK1 (0.53) | PIK3CAMAPK8MAPK9MAPK10MAPK1 | |
| SCHEMBL16125091 | 0.74 | PDGFRB (0.46) | RAB9ANPC1PDGFRBPDGFRAPIK3CA | |
| SCHEMBL17676271 | 0.74 | PDGFRB (0.46) | ALDH1A1RAB9ANPC1PDGFRBPDGFRA | |
| SCHEMBL4697024 | 0.74 | MAPK1 (0.56) | PDGFRBPDGFRAPIK3CAMAPK8MAPK9 | |
| SCHEMBL5757875 | 0.74 | MAPK1 (0.61) | RAB9ANPC1PIK3CAMAPK8MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10004733-B2 | — | — | 2018-06-26 | — | — | US | disclosed |
| US-10004733-B2 | — | — | 2018-06-26 | — | — | US | disclosed |
| US-20160235744-A1 | SUBSTITUTED PYRIDO[2,3-b]PYRAZINES AS FGFR KINASE INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2016-08-18 | — | — | US | disclosed |
| US-9309242-B2 | Substituted pyrido[2,3-b]pyrazines as FGFR kinase inhibitors | ASTEX THERAPEUTICS LTD (GB) | 2016-04-12 | — | — | US | disclosed |
| US-20140288053-A1 | ANTICANCER PYRIDOPYRAZINES VIA THE INHIBITION OF FGFR KINASES | ASTEX THERAPEUTICS LIMITED (GB) | 2014-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10004733-B2 | — | SDHB, SDHA, NDUFS5 | ALDH1A1 205/4885HPGD 217/4885ALOX15 1315/4885 |
| US-20140288053-A1 | ANTICANCER PYRIDOPYRAZINES VIA THE INHIBITION OF FGFR KINASES | FGFR1, FGFR2, FGFR4 | ALDH1A1 1576/4885HPGD 1396/4885ALOX15 2256/4885 |
| US-20160235744-A1 | SUBSTITUTED PYRIDO[2,3-b]PYRAZINES AS FGFR KINASE INHIBITORS | FGFR1, FGFR2, FGFR3 | ALDH1A1 2281/4885HPGD 1710/4885ALOX15 2173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.